• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?

    Simply Wall St·07/30/2026 03:27:41
    Listen to the news
    • CSL recently reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 with hereditary angioedema, showing a safety profile in line with earlier studies and that most participants remained attack-free over 12 months.
    • The company now plans regulatory filings to extend ANDEMBRY’s indication to younger children, potentially widening treatment options in a part of the HAE population where approved long-term prophylactic choices remain limited.
    • We’ll now examine how ANDEMBRY’s strong pediatric data, and the planned label expansion, could shape CSL’s broader investment narrative.

    The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.

    CSL Investment Narrative Recap

    To own CSL, you need to believe its plasma, vaccines and rare-disease portfolio can justify a premium valuation despite recent profit pressure and high debt. The ANDEMBRY pediatric data strengthens the case that newer launches can offset slower headline revenue guidance, but slower uptake across the portfolio and execution around restructuring and the Seqirus demerger still look like the key near term swing factors. The biggest risk remains that cost pressures and competitive pricing keep margins from recovering as expected.

    The ANDEMBRY pediatric readout sits alongside earlier approvals in Europe and Canada for patients 12 and over, underlining how CSL is trying to build a deeper HAE franchise rather than a single-asset story. Together with the recent A$750.0 million buyback and ongoing dividend payments, it reinforces that CSL is balancing reinvestment in growth products with capital returns, at a time when guidance for FY2026 revenue (about US$15.2 billion) already points to a relatively modest top line trajectory.

    Yet investors should also weigh how prolonged margin pressure and restructuring costs could affect earnings more than many expect...

    Read the full narrative on CSL (it's free!)

    CSL's narrative projects $16.9 billion revenue and $3.2 billion earnings by 2029.

    Uncover how CSL's forecasts yield a A$138.19 fair value, a 8% upside to its current price.

    Exploring Other Perspectives

    ASX:CSL 1-Year Stock Price Chart
    ASX:CSL 1-Year Stock Price Chart

    Before this news, the most optimistic analysts were assuming revenues of about US$18.2 billion and earnings of US$3.5 billion by 2029, which is far more upbeat than the baseline view and leans heavily on margin recovery and programs like ANDEMBRY and Seqirus demerger related savings to work out.

    Explore 15 other fair value estimates on CSL - why the stock might be worth as much as 98% more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your CSL research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
    • Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.

    Curious About Other Options?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.